PFSA vs PODD vs DXCM vs ABT

For growth investors, Insulet Corporation (PODD) is the stronger pick with 30.

7% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Abbott Laboratories (ABT) offers the better valuation at 11. 0x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Insulet Corporation (PODD) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

0x versus Insulet Corporation at 45. 5x. On forward P/E, Abbott Laboratories is actually cheaper at 15. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Insulet Corporation wins at 0. 24x versus DexCom, Inc. 's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -18.

3%, compared to -99. 8% for Profusa, Inc. Common Stock (PFSA). Over 10 years, the gap is even starker: PODD returned +480. 2% versus PFSA's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus Profusa, Inc. Common Stock's 2. 99β — meaning PFSA is approximately 1285% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 69% for Insulet Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insulet Corporation (PODD) is pulling ahead at 30.

7% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -39. 8% for Insulet Corporation. Over a 3-year CAGR, PODD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus 0. 0% for Profusa, Inc. Common Stock — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus 0. 0% for PFSA. At the gross margin level — before operating expenses — PODD leads at 71. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Insulet Corporation (PODD) is the more undervalued stock at a PEG of 0. 24x versus DexCom, Inc. 's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Abbott Laboratories (ABT) trades at 15. 4x forward P/E versus 24. 5x for Insulet Corporation — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PODD: 55. 4% to $246. 17.

In this comparison, ABT (2.

6% yield) pays a dividend. PFSA, PODD, DXCM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 6% yield, +166. 7% 10Y return). Profusa, Inc. Common Stock (PFSA) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +166. 7%, PFSA: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PFSA is a small-cap quality compounder stock; PODD is a mid-cap high-growth stock; DXCM is a mid-cap high-growth stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while PFSA, PODD, DXCM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.